Expression of HIF-2a in clear-cell renal cell carcinoma independently predicts overall survival

AbstractThe purpose of this study is to evaluate the expression and the prognostic role of main factors, involved in the hypoxia pathway, in patients with clear-cell renal cell carcinoma (ccRCC). Immunohistochemical expression of Hypoxia inducible factors (HIF) HIF-1a, HIF-2a, prolyl hydroxylases PHD1, PHD2, PHD3, and factor inhibiting HIF (FIH) was assessed on a tissue microarray, containing tumour and corresponding normal kidney tissue from 66 patients underwent surgery for ccRCC. Expression levels were evaluated in relation to T stage, Fuhrman grade, cancer-specific, and overall survival (OS). Cytoplasmatic expression of HIF-2a was positively correlated with expression of HIF-1a (p  = 0.011). HIF-1a expression was also positively correlated with PHD3 and FIH (p  = 0.020 andp  = 0.039). Expression of HIF-1a was associated with lower Fuhrman grade (p  = 0.008), while HIF-2a overexpression with unfavourable grade (p  = 0.026). PHD3 was significant downregulated (84.8%). Age, LDH, presence of necrosis, Fuhrman grade, T stage, and HIF-2a cytoplasmatic expression were significant associated with OS of patients in univariable analysis. In multivariable analysis, HIF-2a expression (p  = 0.006) and T stage (p  = 0.001) remained as the only independent predictors for overall survival. These results indicate that HIF-2a overexpression not only is inversely correlated with Fuhrman grade i...
Source: Medical Molecular Morphology - Category: Molecular Biology Source Type: research

Related Links:

Despite the emphasis on randomized data to guide evidence-based practice, there is a notable lack of clinical trials to inform comparative effectiveness in surgical disciplines. Although this is multifactorial in nature, this paucity ultimately reflects the difficulty associated with conducting surgical trials, particularly in settings where event rates are low (eg, lymph node metastasis in M0 renal cell carcinoma) or when long follow-up is required, as with early-stage disease (eg, low-risk prostate cancer).
Source: Urology - Category: Urology & Nephrology Authors: Source Type: research
Publication date: Available online 23 May 2020Source: European UrologyAuthor(s): David J. Pinato
Source: European Urology - Category: Urology & Nephrology Source Type: research
Conclusion: By linking the NSKCR to several Swedish national databases, a unique database for RCC research has been created. PMID: 32436435 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Urology - Category: Urology & Nephrology Tags: Scand J Urol Source Type: research
CONCLUSIONS: RP11-567G11.1 accelerates the proliferative and invasive abilities of RCC through activating the Notch pathway. Our findings suggest that it may be a new therapeutic target for RCC. PMID: 32432737 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Conclusions: Taken together, we identified the key iron metabolism-related and methylated genes for ccRCC through a comprehensive bioinformatics analysis. This study provides a reliable and robust gene signature for the prognostic predictor of ccRCC patients and maybe provides a promising treatment strategy for this lethal disease.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
British Journal of Cancer, Published online: 22 May 2020; doi:10.1038/s41416-020-0890-yIdentification of low-dose multidrug combinations for sunitinib-naive and pre-treated renal cell carcinoma
Source: British Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
Condition:   Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1 Intervention:   Combination Product: Biological : Toripalimab Drug: Axitinib sunitinib Sponsor:   Shanghai Junshi Bioscience Co., Ltd. Not yet recruiting
Source: - Category: Research Source Type: clinical trials
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Abstract Clear cell renal cell carcinoma (ccRCC) remains one of the most common cancer types globally, and while it has been extensively studied, the molecular basis for its pathology remains incompletely understood. Herein, we profiled three previously published datasets (GSE66272, GSE100666, and GSE105261) in a single integrated analysis aimed at identifying disease-associated patterns of gene expression that may offer mechanistic insight into the drivers of this disease. We pooled expression data from 39 normal kidney samples and 39 kidney tumors, leading us to identify 310 differentially expressed genes (DEGs)...
Source: Aging - Category: Biomedical Science Authors: Tags: Aging (Albany NY) Source Type: research
Tushar A Narain, Gagan Gautam, Amlesh Seth, Vikas K Panwar, Sudhir Rawal, Puneet Dhar, Harkirat S Talwar, Amitabh Singh, Jiten Jaipuria, Ankur MittalIndian Journal of Cancer 2020 57(2):129-138 The Corona Virus Disease-2019 (COVID-19), one of the most devastating pandemics ever, has left thousands of cancer patients to their fate. The future course of this pandemic is still an enigma, but health care services are expected to resume soon in a phased manner. This might be a long drawn process and we need to have policies in place, to be able to fight both, the SARS-CoV-2 virus and cancer, simultaneously, and emerge triumphan...
Source: Indian Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Kidney Cancer | Molecular Biology | Renal Cell Carcinoma | Study | Urology & Nephrology